Best Practices for Monitoring Response to Talquetamab and Optimizing Dosing

EP: 1.Advanced Practice Decision-Making: Patient Selection and Baseline Assessment for Bispecific Therapies

EP: 2.Introducing GPRC5D and MonumenTAL-1 Trial for R/R Multiple Myeloma

EP: 3.Extended Follow-Up From MonumenTAL-1 and APP Clinical Insights on Talquetamab Efficacy Outcomes

EP: 4.Updated Safety Profile of Talquetamab & Concluding Thoughts from MonumenTAL-1

EP: 5.GPRC5D-Related Adverse Effects: Clinical Strategies for Monitoring Patient Care and Safety of Talquetamab

Now Viewing

EP: 6.Best Practices for Monitoring Response to Talquetamab and Optimizing Dosing

When considering dose modifications for talquetamab, clinicians generally prioritize patient symptoms and adverse effects. If patients experience significant toxicities—especially skin or nail changes that can be distressing—treatment is typically held temporarily until symptoms improve. Additionally, if a patient tests positive for respiratory viral infections, treatment is paused for about a week or until the patient is asymptomatic before resuming therapy. This cautious approach helps manage adverse effects while maintaining overall treatment continuity.

For monitoring treatment response, myeloma labs (such as serum protein electrophoresis, free light chains, and M-protein) are checked regularly, typically on day 1 of each treatment cycle or every 3 weeks. For patients with extramedullary disease, imaging with PET-CT scans is used after a few cycles to assess response more precisely. Physical examination remains important, especially for patients with palpable plasmacytomas, which often show rapid regression (“melting”) with therapy, providing a clear clinical indicator of response.

Overall, this approach balances safety and efficacy by individualizing dose adjustments based on toxicity and using both laboratory and imaging modalities to closely monitor disease control during talquetamab treatment.